No Data
No Data
Changyao Holdings: 2024 Semi-Annual Report Summary
Changyao Holdings: 2024 Semi-Annual Report
Changjiang Pharmaceutical Group (300391.SZ) has released its first-half performance, with a net loss of 0.153 billion yuan, an increase of 530.08%.
Changjiang Pharmaceutical Group (300391.SZ) released the 2024 interim report, and the company's revenue was 7365....
Changjiang Pharmaceutical Group (300391.SZ): The net loss in the first half of the year was 0.153 billion yuan.
Changjiang Pharmaceutical Group (300391.SZ) announced its 2024 semi-annual report, with revenue for the reporting period of 73.6537 million yuan, a year-on-year decrease of 84.53%; net income attributable to shareholders of listed companies was -0.153 billion yuan, with a widened year-on-year loss; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was -0.15 billion yuan; basic earnings per share was -0.4355 yuan.
Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) 129% Share Price Surge Not Quite Adding Up
Changjiang Pharmaceutical Group (300391.SZ): Elects Wang Bo as the company's director.
On July 1st, Gelunhui reported that Changjiang Pharmaceutical Group (300391.SZ) held the 17th meeting of the fifth board of directors on July 1, 2024, and approved the Proposal on the Election of the Chairman of the Fifth Board of Directors and the Proposal on the Appointment of the General Manager. The board of directors elected Wang Bo as the chairman of the fifth board of directors of the company, with a term of office consistent with that of the fifth board of directors. The board of directors appointed Hu Shihui as the general manager of the company, with a term of office from the date of appointment to the end of this term of the board of directors. This matter has been approved by the Nomination Committee of the Board of Directors of the Company at its second meeting in 2024.
No Data